Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Compass Therapeutics
Travera Inc
Endeavor Biomedicines, Inc.
Incyte Corporation
BerGenBio ASA
Taproot Health
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Quadriga Biosciences, Inc.
Xencor, Inc.
Incyte Corporation
AbbVie
Novartis
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Swiss Cancer Institute
Novartis
GOG Foundation
Children's Oncology Group
INSYS Therapeutics Inc
University of Chicago
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
Mannkind Corporation